Therapeutic molecules capable of preventing alpha-synuclein misfolding, without abrogating normal functions of physiologically relevant forms of ASYN would therefore be expected to provide clinical benefit for patients with both genetic and sporadic form of PD at all stages of disease. The gene discussed is SNCA; the disease is Parkinson disease.